Tom 8, Nr 2 (2023)
Artykuł przeglądowy
Opublikowany online: 2023-04-27

dostęp otwarty

Wyświetlenia strony 1743
Wyświetlenia/pobrania artykułu 122
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Osteoporosis – a partially recognized challenge for oncology

Krzysztof Jeziorski12
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2023;8(2):109-114.

Streszczenie

Osteoporosis is a huge challenge for medicine, especially public health and geriatrics, but also oncology, because it is a chronic disease requiring long-term, sometimes lifelong care. With the ageing of the population, falls are the third most common cause of disability in the elderly and one of the main reasons for admissions to nursing homes. Although there are approximate data on the incidence of osteoporosis worldwide, there are unfortunately no data on the incidence of osteoporosis in cancerous diseases. The incidence of cancer-related osteoporosis is expected to increase as the inci­dence of cancer in general increases. There are specific problems that concern osteoporosis in cancer patients, including: the mechanisms of development of osteoporosis in cancer diseases, the distinction between cancerous and osteoporotic lesions, undertreatment of patients, the lack of an integrated care system for osteoporosis in cancer patients.

Artykuł dostępny w formacie PDF

Pokaż PDF (angielski) Pobierz plik PDF

Referencje

  1. Tom S, Adachi J, Anderson F, et al. Jr, Frailty and fracture, disability, and falls: a multiple country study from the global longitudinal study of osteoporosis in women. J Am Geriatr Soc. 2013; 61(3): 327–334.
  2. Blain H, Miot S, Bernard PL. How can we prevent falls? In: Falaschi PL, Marsh D. ed. Orthogeriatrics. The management of older patients with fragility fractures. Ed. 1. Springer, Roma. London 2021: 273–290.
  3. EuroSafe, Amsterdam (2015) Falls among older adults in the EU-28: key facts from the available statistics. https://eupha.org/repository/sections/ipsp/Factsheet_falls_in_older_adults_in_EU.pdf.
  4. Adami S, Bertoldo F, Brandi ML, et al. Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo. 2009; 61(4): 260–284.
  5. Kanis J, McCloskey E, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013; 24(1): 23–57.
  6. Falaschi P, Marques A, Giordano S. Osteoporosis and fragility in elderly patients. In: Falaschi P, Marsh D. ed. Orthogeriatrics. The management of older patients with fragility fractures. Ed. 1. Springer, Roma. London 2021: 35–52.
  7. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993; 94(6): 646–650.
  8. Bartl R, Bartl C. The osteoporosis manual. Prevention, diagnosis and management. Springer Nature Switzerland AG 2019: 321–322.
  9. Bartl R, Bartl C. The osteoporosis manual. Prevention, diagnosis and management. Springer Nature Switzerland AG 2019: 89–92.
  10. Kanis J, Borgstrom F, Laet CDe, et al. Assessment of fracture risk. Osteoporos Int. 2004; 16(6): 581–589.
  11. https://ezdrowie.gov.pl/5583?modId=37203.
  12. WHO. Approached February 1, 2020. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health.
  13. Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013; 8(1): 136.
  14. Wojciechowska U, Barańska K, Michałek I, et al. Cancer in Poland in 2020.Polish National Cancer Registry. Warszawa 2022. https://onkologia.org.pl/sites/default/files/publications/2023-01/nowotwory_2020.pdf.
  15. Veronese N, Kolk H, Maggi S. Epidemiology of fragility fractures and social impact. In: Falaschi P, Marsh D. ed. Orthogeriatrics. The management of older patients with fragility fractures. Ed. 1. Springer, Roma. London 2021: 19–33.
  16. Drake MT. Osteoporosis and cancer.\. Curr Osteoporos Rep. 2013; 11(3): 163–170.
  17. Bono CM, Einhorn TA. Overview of osteoporosis: pathophysiology and determinants of bone strength. Eur Spine J. 2003; 12 Suppl 2(Suppl 2): S90–S96.
  18. Bartl R, Bartl C. The osteoporosis manual. Prevention, diagnosis and management. Springer Nature Switzerland AG 2019: 413–416.
  19. Bartl R, Bartl C. The osteoporosis manual. Prevention, diagnosis and management. Springer Nature Switzerland AG 2019: 409–411.
  20. Bartl R, Bartl C. The osteoporosis manual. Prevention, diagnosis and management. Springer Nature Switzerland AG 2019: 389–397.
  21. Ramin C, May BJ, Roden RBS, et al. Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study. Breast Cancer Res. 2018; 20(1): 134.
  22. Bartl R, Bartl C. The osteoporosis manual. Prevention, diagnosis and management. Springer Nature Switzerland AG 2019: 451–461.
  23. Coleman RE, Rubens RD. Bone metastases. In: Abeloff MD, Armitage JO, Niederhuber JE, et al. ed. Clinical Oncology. Ed. 3. Elsevier Churchill Livingstone, Philadelphia 2004: 1091–1128.
  24. Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, et al. Clinical Guidelines Committee of the American College of Physicians. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med. 2023; 176(2): 224–238.
  25. Hildebrand GK, Kasi A. Denosumab. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023 Jan. 2022 Feb 24.
  26. Akel M, Parmar M. Abaloparatide. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023 Jan. 2023 Jan 17.
  27. Merlotti D, Falchetti A, Chiodini I, et al. Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. Expert Opin Pharmacother. 2019; 20(7): 805–811.
  28. Canalis E. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis. Eur J Endocrinol. 2018; 178(2): R33–R44.
  29. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007; 40(6): 1434–1446.
  30. Prather C, Adams E, Zentgraf W. Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis. Am J Health Syst Pharm. 2020; 77(23): 1949–1956.
  31. Muchmore DB. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist. 2000; 5(5): 388–392.
  32. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019; 393(10169): 364–376.
  33. Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009; 122(2 Suppl): S3–13.
  34. Imaz I, Zegarra P, González-Enríquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010; 21(11): 1943–1951.
  35. Solomon DH, Johnston SS, Boytsov NN, et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014; 29(9): 1929–1937.
  36. Ström O, Borgström F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2011; 6: 59–155.
  37. Greenspan SL, Wyman A, Hooven FH, et al. Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatri Soc. 2012; 60(3): 455–461.
  38. Kim SC, Kim MS, Sanfélix-Gimeno G, et al. Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med. 2015; 128(5): 519–526.e1.
  39. van der Velde RY, Wyers CE, Teesselink E, et al. Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: Variation by age, sex, geographic location and ethnicity. Bone. 2017; 94: 50–55.
  40. Walters S, Khan T, Ong T, et al. Fracture liaison services: improving outcomes for patients with osteoporosis. Clin Interv Aging. 2017; 12: 117–127.
  41. Bonanni S, Sorensen AA, Dubin J, et al. The Role of the Fracture Liaison Service in Osteoporosis Care. Mo Med. 2017; 114(4): 295–298.



Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory